SeekingAlpha · Oct 19, 2026
Vaxcyte: Vaccine Titan In The Making
Vaxcyte is a late clinical-stage vaccine company positioned as a potential disruptor in the vaccine market. Learn more about PCVX stock here.
PC
NASDAQ · PCVX
Vaxcyte, Inc. Common Stock
Healthcare · Biotechnology
$62.03
Down-$0.58 (-0.93%)
Updated Oct 31, 2026, 3:17 AM
SID Score
6.6/10
Composite research score
Smart Money
55/100
Neutral
- Market cap
- 5.84B
- P/E ratio
- -9.24
- Dividend yield
- 0.00%
- 52-week range
- $39.87 – $90.75
- Volume
- 1.71M
- Avg. volume
- 1.73M
Price performance · PCVX
PCVX price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
PCVX closed at $62.03 after 21 trading sessions, up 9.83% for the selected period.
- Last close
- $62.03
- Period change
- +9.83%
- Period low
- $56.48
- Period high
- $73.82
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $62.59 | $63.275 | $61.0204 | $62.03 | 1.71M |
| Oct 29, 2026 | $61.88 | $63.14 | $61.64 | $62.61 | 2.01M |
| Oct 28, 2026 | $59.92 | $63.94 | $59.58 | $61.46 | 2.21M |
| Oct 27, 2026 | $59.92 | $61.30 | $59.43 | $60.67 | 2.59M |
| Oct 26, 2026 | $60.68 | $61.50 | $59.19 | $59.97 | 1.47M |
| Oct 23, 2026 | $62.35 | $62.77 | $60.27 | $60.43 | 2.06M |
| Oct 22, 2026 | $62.96 | $64.58 | $61.56 | $62.85 | 2.77M |
| Oct 21, 2026 | $66.02 | $67.465 | $63.09 | $63.23 | 3.27M |
| Oct 20, 2026 | $63.80 | $67.01 | $63.68 | $66.23 | 1.96M |
| Oct 19, 2026 | $64.14 | $66.0188 | $63.375 | $63.68 | 2.55M |
| Oct 16, 2026 | $65.13 | $65.34 | $62.54 | $63.62 | 3.25M |
| Oct 15, 2026 | $67.72 | $68.33 | $65.00 | $65.27 | 2.45M |
| Oct 14, 2026 | $67.07 | $69.205 | $66.00 | $67.55 | 1.53M |
| Oct 13, 2026 | $70.58 | $71.09 | $66.63 | $66.80 | 2.81M |
| Oct 12, 2026 | $71.08 | $72.89 | $68.97 | $70.65 | 2.43M |
| Oct 9, 2026 | $64.78 | $72.44 | $64.78 | $71.38 | 4.38M |
| Oct 8, 2026 | $67.14 | $67.97 | $63.79 | $65.015 | 3.85M |
| Oct 7, 2026 | $65.86 | $67.15 | $64.27 | $66.96 | 11.56M |
| Oct 6, 2026 | $73.35 | $73.395 | $63.8997 | $66.70 | 10.16M |
| Oct 5, 2026 | $87.21 | $90.75 | $71.60 | $73.82 | 14.92M |
| Oct 2, 2026 | $56.76 | $57.00 | $55.84 | $56.48 | 2.4M |
Latest PCVX news
The latest Smart Investors Daily articles mentioning PCVX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
PCVX research
Overview
Company profile and research snapshot.
Company profile
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $77.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 12, 2026 | Cantor Fitzgerald | Overweight | — |
| Oct 5, 2026 | Needham | Buy | — |
| Oct 5, 2026 | BTIG | Buy | — |
| Oct 5, 2026 | Guggenheim | Buy | — |
| Sep 28, 2026 | B of A Securities | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 14, 2026
Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 75.6% in Vaxcyte (PCVX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Benzinga · Oct 12, 2026
Cantor Fitzgerald Reiterates Overweight on Vaxcyte, Announces $120 Price Target
Cantor Fitzgerald analyst Carter Gould reiterates Vaxcyte (NASDAQ:PCVX) with a Overweight and announces $120 price target.
Benzinga · Oct 12, 2026
Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'
Stephen King slammed Trump’s incoming press secretary over her vaccine conspiracy theories and controversial posts.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
